The Corporation focussed on the Biology of healing has recently announced further data from the ongoing PBI-4050 study in Alström syndrome patients as well as 2017 results and an update on its other programs. The average treatment duration of PBI-4050, for the 12 Alström patients, has reached 52 weeks and further clinical activity in the heart and liver was observed with longer treatment exposure. We had already seen promising data on the liver and this has been corroborated by addi
06 Apr 2018
Strong data on PBI 4050 ahead of key regulatory meetings. Ryplazim™ BLA amendment a manageable delay.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong data on PBI 4050 ahead of key regulatory meetings. Ryplazim™ BLA amendment a manageable delay.
ProMetic Life Sciences (PLI:TSE) | 0 0 1.3% | Mkt Cap: 1,075m
- Published:
06 Apr 2018 -
Author:
Derren Nathan -
Pages:
9
The Corporation focussed on the Biology of healing has recently announced further data from the ongoing PBI-4050 study in Alström syndrome patients as well as 2017 results and an update on its other programs. The average treatment duration of PBI-4050, for the 12 Alström patients, has reached 52 weeks and further clinical activity in the heart and liver was observed with longer treatment exposure. We had already seen promising data on the liver and this has been corroborated by addi